Mannkind (MNKD) Other Accumulated Expenses (2011 - 2026)
Mannkind (MNKD) reported Other Accumulated Expenses of $2.8 million for Q1 2026, down 23.58% year-over-year from $3.6 million in Q1 2025, and down 7.09% on a QoQ basis from $3.0 million in Q4 2025.
Mannkind (MNKD) has 16 years of Other Accumulated Expenses data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Other Accumulated Expenses fell 23.58% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 23.58% YoY) and the FY2025 annual result came in at $3.0 million, down 31.34% from the prior year.
- Other Accumulated Expenses declined to $2.8 million in Q1 2026 per MNKD's latest filing, from $3.0 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $5.6 million in Q2 2024 and bottomed at $2.5 million in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $4.1 million (2025), against an average of $4.0 million.
- The widest annual swing landed in 2022, when Other Accumulated Expenses soared 138.33%; it then plunged 33.51% in 2025.
- Tracing MNKD's Other Accumulated Expenses over 5 years: stood at $4.7 million in 2022, then rose by 16.97% to $5.5 million in 2023, then fell by 21.11% to $4.4 million in 2024, then sank by 31.34% to $3.0 million in 2025, then declined by 7.09% to $2.8 million in 2026.
- Per Business Quant, the three latest MNKD Other Accumulated Expenses figures stand at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $4.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 4.06 Mn |
| Jun 30, 2025 | 4.52 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 5.59 Mn |
| Mar 31, 2024 | 5.47 Mn |
| Dec 31, 2023 | 5.52 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 4.72 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 3.33 Mn |
| Mar 31, 2022 | 2.47 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.56 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 958,000.00 |
| Sep 30, 2020 | 796,000.00 |
| Jun 30, 2020 | 594,000.00 |
| Mar 31, 2020 | 863,000.00 |
| Dec 31, 2019 | 1.30 Mn |
| Sep 30, 2019 | 372,000.00 |
| Jun 30, 2019 | 1.57 Mn |
| Mar 31, 2019 | 983,000.00 |
| Dec 31, 2018 | 1.32 Mn |
| Sep 30, 2018 | 806,000.00 |
| Jun 30, 2018 | 1.07 Mn |
| Mar 31, 2018 | 962,000.00 |
| Dec 31, 2017 | 472,000.00 |
| Sep 30, 2017 | 722,000.00 |
| Jun 30, 2017 | 496,000.00 |
| Mar 31, 2017 | 799,000.00 |
| Dec 31, 2016 | 355,000.00 |
| Sep 30, 2016 | 200,000.00 |
| Jun 30, 2016 | 3.11 Mn |
| Mar 31, 2016 | 2.19 Mn |
| Dec 31, 2015 | 483,000.00 |
| Sep 30, 2015 | 3.09 Mn |
| Jun 30, 2015 | 3.04 Mn |
| Mar 31, 2015 | 3.39 Mn |
| Dec 31, 2014 | 7.54 Mn |
| Sep 30, 2014 | 12.27 Mn |
| Jun 30, 2014 | 4.21 Mn |
| Mar 31, 2014 | 5.72 Mn |
| Dec 31, 2013 | 5.71 Mn |
| Jun 30, 2013 | 1.71 Mn |
| Mar 31, 2013 | 1.72 Mn |
| Dec 31, 2012 | 1.30 Mn |
| Dec 31, 2011 | 1.09 Mn |